Yes, indeed. Assuming efficacy/safety is just the same for the device and DC VAX L across the spectrum, I mentioned QOL(to your point) and ease of administration as additional evaluative factors. I would think that patients would overwhelmingly select the vaccine. There may be cases where the device conceivably has greater efficacy and thus might be selected, however, it appears that at least wrt to the major classifications, M+ and M-, both therapies follow similar patterns. Bottom line, I think with reasonable positive results, the RAs would approve DC Vax L to provide patients with more alternatives.
News 
Market Data 
Discover 
